New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase
申请人:PFIZER INC.
公开号:EP0418071B1
公开(公告)日:1995-04-26
US5362878A
申请人:——
公开号:US5362878A
公开(公告)日:1994-11-08
US5656634A
申请人:——
公开号:US5656634A
公开(公告)日:1997-08-12
[EN] NEW (N)-ARYL AND (N)-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT)
申请人:PFIZER INC.
公开号:WO1991004027A1
公开(公告)日:1991-04-04
(EN) Compounds of formula (I), the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula (I) are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidermic and antiatherosclerosis agents.(FR) L'invention concerne les composés de la formule (I), ces sels pharmaceutiquement acceptables, dans laquelle Q et R1 sont définis ci-dessous, ainsi que des nouveaux intermédiaires d'acide carboxylique et d'halogénure d'acide utilisés dans la synthèse desdits composés. Les composés de la formule (I) sont des inhibiteurs de l'acyl coenzyme A: cholestérol acyltransférase (ACAT) et sont utiles en tant qu'agents hypolipidermiques et antiathérosclérose.
Intermediates for making N-aryl and N-heteroarylamide and urea
申请人:Pfizer Inc.
公开号:US05362878A1
公开(公告)日:1994-11-08
Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.